Want to see PRTA full AI Analyst Report?
Revenue by Segment
Shows how much revenue each business segment generates, highlighting which parts of the company are driving growth and which may need strategic adjustments.Revenue is clearly episodic—driven by partner milestone and license payments rather than recurring product sales—so pronounced spikes represent one‑off partner payments tied to clinical progress. Management highlighted meaningful near‑term upside (up to $105M in 2026 and larger multi‑billion potential milestones) but excludes these from base guidance, so cash runway and valuation hinge on milestone timing and partner decisions. Model Prothena as event‑driven: focus on upcoming partner catalysts and cash burn, not steady organic revenue growth.
Date | Collaboration | License and Intellectual Property |
|---|---|---|
Jun 30, 2026 | $1.01M | $0.00 |
Mar 31, 2026 | $1.03M | $50.05M |
Dec 31, 2025 | $21.00K | $0.00 |
Sep 30, 2025 | $2.42M | $0.00 |
Jun 30, 2025 | $4.42M | $0.00 |
Mar 31, 2025 | $2.78M | $50.00K |
Dec 31, 2024 | $2.12M | $0.00 |
Sep 30, 2024 | $970.00K | $0.00 |
Jun 30, 2024 | $132.01M | $0.00 |
Mar 31, 2024 | $0.00 | $50.00K |